2,4-diaminopyrimidine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, F; Li, J; Qiu, Y; Tan, G; Wang, W; Xu, K; Yang, F; Zhang, J; Zou, Z | 1 |
1 other study(ies) available for 2,4-diaminopyrimidine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Nitric Oxide; Triple Negative Breast Neoplasms | 2023 |